Clinical trials: Infiltrating Cervical Carcinoma
Ovarian Carcinoma, Cervical Carcinoma
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
Multicenter ambispective observational study (prospective/retrospective)
- Conditions
- Ovarian Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Vulvar Carcinoma
- Trial name
- NCT07267780
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute, Naples
Squamous Cell Carcinoma of the Head and Neck
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Multicenter, multicohort, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145/LN-145-S1) followed by IL-2…
- Trial name
- NCT03083873
- Testing
- LN-145, LN-145-S1
- Where
- 22 sites in United States
- Volunteers
- 64 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Infections, Papillomavirus, Cervical Cancer
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
The aim of the study is to assess the distribution of the most frequent types of human papillomavirus in African women diagnosed with invasive cervical cancer.
- Trial name
- NCT01207999
- Testing
- Collection of cervical cancer tissue samples, Data collection
- Where
- 5 sites in Ghana, Nigeria and 1 more
- Volunteers
- 591 people
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Precancerous Condition
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in…
- Trial name
- NCT00128661
- Testing
- human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine
- Where
- Costa Rica
- Volunteers
- 7,466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Locally Advanced Head and Neck Squamous Cell Carcinoma
Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC
First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell Infiltration.
- Trial name
- NCT03426657
- Testing
- Durvalumab + Tremelimumab + RT
- Where
- 7 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Oral Squamous, Cell Carcinoma
Radio/Pathological Evaluation of Tongue Cancer Infiltration
The aim of the study is to assess the good correlation and prediction of the DOI for the post-operative pathological results and prognosis.
- Trial name
- RaP E ToC (NCT04821128)
- Testing
- Radiologic and pathological review.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Cervical Cancer, Cervical Cancer Stage
Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB
The purpose of this study is to find out whether patients with cervical cancer treated with about a new radiation technique called "stereotactic body radiotherapy (SBRT) have less stress and anxiety compared to standard…
- Conditions
- Cervical Cancer, Cervical Cancer Stage, Cervical Cancer Stage IB2, Cervical Cancer Stage IB1
- Trial name
- NICER (NCT03146039)
- Testing
- Radiation Therapy
- Where
- United States
- Sponsor
- University of California, San Diego
Cervical Intraepithelial Neoplasia
Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9
This study evaluates the impact on disease relapse of presurgical 9-valent HPV vaccination versus placebo vaccination in women treated with LEEP (loop electrosurgical excision procedure) for CIN2+ (high grade cervical…
- Trial name
- HOPE9 (NCT03848039)
- Testing
- Gardasil-9
- Volunteers
- 1,220 people
- Sponsor
- Alessandro Ghelardi
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Nasopharyngeal Carcinoma, Hepatocellular Carcinoma
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
Background: T cell based adoptive immunotherapy including CTL and TIL may stimulated the immune system and stop cancer cells from growing.
- Conditions
- Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Breast Carcinoma
- Trial name
- NCT01462903
- Testing
- tumor infiltrating lymphocytes, IL-2
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer, Vulvar Cancer
CaptHPV : Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas
The current project is based on the assumption that a diagnosis of human papillomavirus associated Infiltrating Carcinomas can be made from a blood sample for patient with Cervical Cancer, Vulvar Cancer, Anal Cancer, Oropharynx…
- Conditions
- Cervical Cancer, Vulvar Cancer, Anal Cancer, Oropharynx Cancer
- Trial name
- CaptHPV (NCT02981862)
- Testing
- CaptHPV method
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut de Cancérologie de Lorraine
Cervical Intraepithelial Neoplasia, Invasive Cervical Cancer
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way…
- Trial name
- NCT06191133
- Testing
- Fenofibrate, Cervical Conization, Hysterectomy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Lindsay Ferguson, MD
Cervical Cancer, Precancerous Condition
Identifying Genes That Predict Risk of Developing Cervical Intraepithelial Neoplasia or Invasive Cervical Cancer
RATIONALE: Finding certain changes in genes may help doctors predict which patients are at risk of developing cervical intraepithelial neoplasia or invasive cervical cancer and may help the study of cancer in the future.
- Trial name
- NCT00458562
- Where
- 2 sites in Senegal
- Volunteers
- 1,680 people
- Sponsor
- University of Washington
Cervical Carcinoma
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by…
- Trial name
- NCT03108495
- Testing
- LN-145, LN-145 + pembrolizumab
- Where
- 43 sites in United States, France and 6 more
- Volunteers
- 210 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Platinum-resistant Ovarian Cancer, Endometrial Cancer
A Study of DeTIL-0255 in Adults With Advanced Malignancies
This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.
- Conditions
- Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT05107739
- Testing
- Drug Product De-TIL-0255
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nurix Therapeutics, Inc.
Cervical Cancer
Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand
The aim of this study is to assess the distribution of the most frequent types of human papillomavirus in women diagnosed with invasive cervical cancer in New Zealand.
- Trial name
- NCT01328028
- Testing
- Testing of archived cervical cancer tissue samples, Data collection
- Volunteers
- 244 people
- Sponsor
- GlaxoSmithKline
Kita-kyushu Lung Cancer Antigen 1, Human
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Background: Researchers have found a new way to treat cancer using T cell therapy. The therapy used in this study is T Cell Receptor (TCR) Gene Therapy Targeting Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1), a cancer germline…
- Trial name
- NCT05035407
- Testing
- IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Evaluation of the Cancer Tracking System (CATSystem)
Cervical cancer contributes to significant preventable mortality in Kenya where less than 20% of women are screened. The Cancer Tracking System (CATSystem) is a web-based, algorithm generated tool to promote guideline adherent…
- Trial name
- CATSystem (NCT06286462)
- Testing
- Cancer Tracking System (CATSystem)
- Where
- 10 sites in Kenya
- Volunteers
- 6,600 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Cervical Cancer
Cervical Cancer in French Guiana: Screening Between 2006-2011
Given that cervical cancer is the second most frequent cancer among women in french guiana the aim of the study was to determine the screening rate among women living in French Guiana.
- Trial name
- DepCol (NCT02903693)
- Testing
- cross sectional
- Where
- France
- Volunteers
- 91,458 people
- Sponsor
- Centre Hospitalier de Cayenne
HNSCC
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head and neck tumor subjects with safety…
- Trial name
- NCT06190275
- Testing
- GT201 in combination with PD-1 inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Grit Biotechnology